Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome.
The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital.
For more information, visit www.ocelotbio.com.
Company Details
- Employees
- 3
- Founded
- -
- Address
- 601 Marshall Street,
- Phone
- +1 530 320 7230
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ocelotbio.com
- HQ
- Redwood City, CA
Ocelot Bio Questions
Ocelot Bio's helpline number is +1 530 320 7230
Ocelot Bio's website is ocelotbio.com
Ocelot Bio's LinkedIn profile is https://www.linkedin.com/company/ocelot-bio
Ocelot Bio has
3 employees.
View email and phone details for 3
employees at Ocelot Bio.
Ocelot Bio's industry is
Biotechnology Research
Ocelot Bio's top competitors are
Vivo Capital,
Biotech Ceo Sisterhood,
Corxel Pharmaceuticals,
Vertex Pharmaceuticals,
Graphite Bio,
Narwhal Bio Inc.,
Excellergy,
Fauna Bio,
Madrigal Pharmaceuticals,
Metacrine, Inc..
Ocelot Bio's categories are Biotechnology Research
Ocelot Bio's founding year is 2020
